{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:41:26Z","timestamp":1698572486061},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6155,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1996,5]]},"abstract":"<jats:p>The pharmacokinetics and safety of a novel, long\u2010acting, prodrug\u2010type K<jats:sup>+<\/jats:sup>\u2010channel opener, Y\u201027152, were investigated in healthy male volunteers. In the first phase, single oral doses of 0.1, 0.25, 0.5, 0.75, and 1.0 mg of Y\u201027152 (n = 3\u20136 per dose) were given after overnight fasts in a dose\u2010escalating manner. The 0.75\u2010mg dose was given both after an overnight fast or after food to examine the effects of food intake. In the second phase, multiple doses of Y\u201027152 were taken after meals once daily for 7 consecutive days. In part A of this phase, either placebo (n = 3) or 0.5 mg of Y\u201027152 (n = 6) was taken for 7 days, and in part B of this phase 0.5\u2010, 0.75\u2010, and 1.0\u2010mg doses were taken in a dose\u2010escalating manner for 1, 3, and 3 days, respectively (n = 9). In the single\u2010dose study, peak concentration (C<jats:sub>max<\/jats:sub>) and area under the plasma concentration\u2010time curve (AUC) of main active metabolite (Y\u201026763; M1) increased in parallel with dosage. This dose\u2010linearity was less obvious with Y\u201027152, which had an AUC approximately 6 to 10 times less than that of M1. Administration with food at 0.75 mg resulted in a small but significant decrease (\u223c10%) in the C<jats:sub>max<\/jats:sub> and AUC of M1. At doses of 0.5 mg or higher, participants experienced headaches and palpitations, which were probably due to the vasodilatory effects and did not require treatment. Mean diastolic blood pressure significantly decreased and pulse rate increased at doses of 0.5 mg or higher compared with predose values. Plasma renin activity was significantly elevated 4 hours after the administration of the 0.75\u2010 and 1.0\u2010mg doses, but showed no significant change at 0.5 mg. In the multiple\u2010dose study, the time profile of the plasma concentration of M1 approximately coincided with the simulation curves worked out using the pharmacokinetic parameters obtained in the single\u2010dose study. The incidence of headaches tended to increase with dose in part B, but drug administration was not discontinued in any case. Plasma renin activity again increased 4 hours after administration. In phase B of the multiple\u2010dose study, diastolic blood pressure decreased and pulse rate increased compared with predose values. Y\u201027152 was metabolized to M1 and well tolerated in healthy volunteers, and its pharmacologic effects were likely caused by vasodilation, which could make it an effective antihypertensive agent.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1996.tb05031.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:37:15Z","timestamp":1362767835000},"page":"439-451","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and Safety of a Novel, Long\u2010Acting, Prodrug\u2010Type Potassium Channel Opener, Y\u201027152, in Healthy Volunteers"],"prefix":"10.1002","volume":"36","author":[{"given":"Toshihiko","family":"Uematsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kosuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei\u2010ichi","family":"Hirosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinobu","family":"Kadobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(88)90238-6"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542128"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90355-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)91129-T"},{"issue":"7","key":"e_1_2_1_6_2","first-page":"67","article-title":"Comparative study of pinacidil and nifedipine in the treatment of arterial hypertension","volume":"36","author":"Jurgensen HJ","year":"1982","journal-title":"Drugs"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1991.tb00422.x"},{"key":"e_1_2_1_8_2","first-page":"730","article-title":"Y\u201027152, a long\u2010acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state","volume":"261","author":"Nakajima T","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803050-00001"},{"key":"e_1_2_1_10_2","volume-title":"The Hemorrhagic Disorders.","author":"Stefanini M","year":"1962"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.20.139"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.117"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05611.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199311000-00008"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90355-8"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1996.tb05031.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1996.tb05031.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T15:56:11Z","timestamp":1698422171000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1996.tb05031.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["10.1002\/j.1552-4604.1996.tb05031.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb05031.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]}}}